$62.45▾ 0.49%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$92.70MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+48.2%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Travere Therapeutics, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Still growing fast, but the pace has been easing.
Key numbers
Valuation
EPS (TTM)$-0.46
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-7.4%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$591.33M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days2 articles
0 bullish0 neutral2 bearish
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.